Cholesterol and Radiosensitivity
- 100 Downloads
Although there is some evidence in animal studies that cholesterol signaling mediates radiation sensitivity of normal tissues, until recently, no connection had been made between cholesterol signaling and tumor radiosensitivity. Aberrant cholesterol signaling in breast cancer promotes oncogenesis and tumor progression by either altering membrane fluidity, membrane associated rafts, or as a direct activator of transcription. Cholesterol is synthesized de novo by the mevalonate pathway. A causal role for hydroxy-3-methylglutaryl-coenzyme A reductase, a rate-limiting enzyme of the mevalonate pathway, in oncogenic transformation, progression, and sensitivity to treatment offers an opportunity for drugs that inhibit this enzyme (i.e., statins) as well as other cholesterol mediating strategies as radiosensitizing treatments. This review discusses potential mechanisms by which statins alter cholesterol signaling in breast cancer and potentially enhances radiation sensitivity and outcome with a special focus on inflammatory breast cancer.
KeywordsCholesterol metabolism Statins Radiation therapy Tumor-initiating cells FOXO3a HDL Inflammatory breast cancer
This work was supported by the National Institutes of Health R01CA138239-01 and 1R01CA180061-01, the State of Texas Grant for Rare and Aggressive Breast Cancer Research Program, the Inflammatory Breast Cancer Network Grant, and an institutional research grant from The University of Texas MD Anderson Cancer Center. The Research Animal Support Facility-Houston, Small Animal Imaging Facility, Flow Cytometry and Cellular Imaging Facility, and Research Histopathology Facility are supported in part by the National Institutes of Health through MD Anderson Cancer Center Support (core) Grant CA016672.
Compliance with Ethical Standards
Conflict of Interest
Omar M. Rahal and Wendy A. Woodward declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.••Wolfe AR et al. High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2015;91:1072–80. doi: 10.1016/j.ijrobp.2014.12.039. This is the first study to link dyslipidemia with cancer stem cell self-renewal and radiation response in inflammatory breast cancer. CrossRefPubMedGoogle Scholar
- 2.••Butt S et al. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy. Ann Surg Oncol. 2014;21:2911–9. doi: 10.1245/s10434-014-3708-4. This paper provides clinically relevant evidence demonstrating that the main target of statins, HMGCR, is highly expressed in early stage breast cancer and predicts response to radiation therapy. Data strongly supports HMCGR as a biomarker of response to radiation therapy alone or in combination with statins. CrossRefPubMedGoogle Scholar
- 10.••Nguyen VT et al. Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nat Commun. 2015;6:10044. doi: 10.1038/ncomms10044. This study elucidated a novel mechanism of resistance to aromatase inhibitors (AI) in breast cancer via enhanced cholesterol biosynthesis. Importantly, Statin treatment decreased 27-hydroxycholesterol-mediated estrogen receptor binding and cell invasion of AI-resistant breast cancer cells. CrossRefPubMedPubMedCentralGoogle Scholar
- 13.••Wolfe AR et al. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Res Treat. 2015;154:495–508. doi: 10.1007/s10549-015-3645-3. Strong pre-clinical evidence is provided demonstrating that statins inhibit lung and brain metastasis of TNBC and IBC cells in a variety of in vivo mouse models. Mechanistically, statin mediated effects occur through stabilization of FOXO3a. CrossRefPubMedGoogle Scholar
- 20.•Nelson ER et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342:1094–8. doi: 10.1126/science.1241908. Data presented in this study proved a causal effect of cholesterol metabolite 27-hydroxycholesterol in ER-dependent growth and LXR-mediated metastasis of hormone positive breast cancer. Further it supports design of future clinical trials of statins alone or in combination with hormonal therapies for ER-positive breast cancer. CrossRefPubMedPubMedCentralGoogle Scholar
- 21.•Pelton K et al. Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol. 2014;184:2099–110. doi: 10.1016/j.ajpath.2014.03.006. This study used a well-controlled preclinical mouse model of hypercholesterolemia to demonstrate that high serum cholesterol levels are associated with accelerated breast cancer growth and microvessel density of orthotopically implanted MDAMB231 cells. CrossRefPubMedPubMedCentralGoogle Scholar
- 26.••Lacerda L et al. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med. 2014;3:849–56. doi: 10.5966/sctm.2013-0204. This study demonstrated an association between statin used and increased locoregional recurrence free survival after postmastectomy radiation therapy in IBC patients and provided evidence of statin-mediated radiosensitization of TICs of IBC. CrossRefPubMedPubMedCentralGoogle Scholar
- 31.••Lenarczyk M et al. Simvastatin mitigates increases in risk factors for and the occurrence of cardiac disease following 10 Gy total body irradiation. Pharmacol Res Perspect. 2015;3:e00145. doi: 10.1002/prp2.145. Data from this important paper demonstrates that statins can inhibit undesired effects of total body irradiation systemic and non systemic effects on normal tissue such as cardiac dysfunction, cellular fibrosis, and increased content of systemic LDL and triglycerides. It supports the use of statins along with radiation therapy for breast cancer to target cancer cells with dysregulated mevalonate pathway while protecting against cardiac disease. CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Out R et al. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol. 2008;28:258–64. doi: 10.1161/ATVBAHA.107.156935.CrossRefPubMedGoogle Scholar
- 48.Wolfe, A. et al. MiR-33a negatively regulates high-density lipoprotein-induced radiation sensitivity in breast cancer. Int J Rad Biol Oncol Phys (2016).Google Scholar
- 49.••Woodward WA. Inflammatory breast cancer: unique biological and therapeutic considerations. Lancet Oncol. 2015;16:e568–76. doi: 10.1016/S1470-2045(15)00146-1. This review provides the latest update on IBC biology and treatment. Furthermore, it offers a new perspective on targeting the tumor microenvironment from a radiation oncology point of view. CrossRefPubMedGoogle Scholar
- 53.••Bjarnadottir O et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013;138:499–508. doi: 10.1007/s10549-013-2473-6. This study demonstrated that effect of pre-operative administration of atorvastatin in breast cancer patients is associated with decreased proliferation (lower Ki67) in HMGCR-positive tumors and supports future trials to evaluate HMGCR expression as a predictive biomarker of response to statins in breast cancer. CrossRefPubMedGoogle Scholar